Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
Español
English
Русский
中文
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
FATE
#3071
Fate Therapeutics, Inc.
1.4
8
+2.07%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+2.07%
Monthly Change
+12.12%
6 month change
+28.70%
Year Change
+39.62%
Previous Close
1.4
5
Open
1.4
8
Bid
Ask
Low
1.4
8
High
1.4
8
Volume
50
Markets
US Stock Market
Healthcare
FATE
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
113.89 M
114.6 M
114.63 M
115.33 M
115.35 M
116.26 M
—
Valuation ratios
Enterprise value
360.72 M
153.03 M
45.65 M
87.92 M
104.72 M
67.62 M
305.92 M
Price to earnings ratio
-2.12
-1.01
-0.53
-0.77
-0.95
-0.85
-3.11
Price to sales ratio
29.21
13.76
6.94
15.49
20.71
—
—
Price to cash flow ratio
2.85
1.53
0.75
1.13
1.34
1.1
4.32
Price to book ratio
0.24
0.59
0.07
0.11
0.13
0.56
0.87
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.1
0.12
0.09
0.09
0.09
0.1
0.38
Return on equity %
0.13
0.16
0.13
0.13
0.14
0.16
0.55
Return on invested capital %
—
-13.31
—
—
—
-79.08
—
Gross margin %
100
100
100
100
100
100
400
Operating margin %
1 703.87
3 319.78
2 534.07
1 938.54
1 995.12
2 536.23
9 003.96
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
1 551.01
2 803.92
2 309.45
1 786.58
1 852.38
2 364.79
8 313.2
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
8.29
7.58
8.81
8.04
7.87
5.79
30.51
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.01
0
0
0
0
0
0.02
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.25
0.24
0.29
0.21
0.2
0.2
0.89
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
2.52
0.32
2.03
1.88
1.81
1.71
7.44
Net current asset value per share
2.63
2.57
2.1
1.94
1.86
1.76
7.66
Tangible book value per share
3.08
2.8
2.44
2.21
1.97
1.74
8.35
Working capital per share
2.32
2.23
1.86
1.7
1.62
1.45
6.64
Book value per share
3.08
2.8
2.44
2.21
1.97
1.74
8.35
News
Baird reitera la calificación de las acciones de Fate Therapeutics por el progreso del ensayo
Baird reitera calificación de Fate Therapeutics por avance en ensayos
Baird reiterates Fate Therapeutics stock rating on trial progress
Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates
Fate Therapeutics superaron las previsiones de BPA en el cuarto trimestre del año
Fate Therapeutics supera por las previsiones de BPA en el cuarto trimestre del año
Fate Therapeutics earnings beat, revenue topped estimates
Fate Therapeutics reports positive lupus treatment data at ASH meeting
Fate Therapeutics superaron 0.03$ las previsiones de BPA en el tercer trimestre del año
Fate Therapeutics supera por 0,03$ las previsiones de BPA en el tercer trimestre del año
Fate Therapeutics earnings beat by $0.03, revenue topped estimates
Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates